Prognostic and Safety Implications of Renin-Angiotensin-Aldosterone System Inhibitors in Hypertrophic Cardiomyopathy: A Real-World Observation Over 2,000 Patients

[1]  Y. Yoon,et al.  Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction , 2022, Heart.

[2]  Seung‐Pyo Lee,et al.  Augmented risk of ischemic stroke in hypertrophic cardiomyopathy patients without documented atrial fibrillation , 2022, Scientific Reports.

[3]  Yong-Jin Kim,et al.  Major Clinical Issues in Hypertrophic Cardiomyopathy , 2022, Korean circulation journal.

[4]  Yong-Jin Kim,et al.  Age-related sex differences in the outcomes of patients with hypertrophic cardiomyopathy , 2022, PloS one.

[5]  M. Desai,et al.  Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. , 2022, Journal of the American College of Cardiology.

[6]  Amit R. Patel,et al.  Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial , 2021, Nature Medicine.

[7]  G. Cho,et al.  Supplementary role of left ventricular global longitudinal strain for predicting sudden cardiac death in hypertrophic cardiomyopathy. , 2021, European heart journal. Cardiovascular Imaging.

[8]  Minkwan Kim,et al.  Sex differences in the prognosis of patients with hypertrophic cardiomyopathy , 2021, Scientific Reports.

[9]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Journal of the American College of Cardiology.

[10]  Yong-Jin Kim,et al.  Obesity and metabolic health status are determinants for the clinical expression of hypertrophic cardiomyopathy , 2019, European journal of preventive cardiology.

[11]  E. Tay,et al.  Effect of Renin-Angiotensin Blockers on Left Ventricular Remodeling in Severe Aortic Stenosis. , 2017, The American journal of cardiology.

[12]  S. Ommen,et al.  Comparison of Maximal Wall Thickness in Hypertrophic Cardiomyopathy Differs Between Magnetic Resonance Imaging and Transthoracic Echocardiography. , 2017, The American journal of cardiology.

[13]  R. Wachter,et al.  Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens , 2016, European journal of heart failure.

[14]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[15]  P. Kolh,et al.  Guidelines on the diagnosis and management of acute pulmonary embolism The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology ( ESC ) Endorsed by the European Respiratory Society ( ERS ) , 2014 .

[16]  C. Mady,et al.  Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. , 2005, The American journal of cardiology.